Last reviewed · How we verify

NCT05018091

Dexamethasone in Total Knee Arthroplasty

Completed Phase 4 Last updated 3 August 2025
What this trial tests

Phase 4 trial testing Dexamethasone 4mg in Total Knee Arthroplasty in 404 participants. Completed in 30 May 2025.

Timeline
28 October 2021
Primary endpoint
1 January 2025
30 May 2025

Quick facts

Lead sponsorRush University Medical Center
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment404
Start date28 October 2021
Primary completion1 January 2025
Estimated completion30 May 2025
Sites10 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Rush University Medical Center

Who can join

18 and older, any sex, with Total Knee Arthroplasty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexamethasone 4mg

Trials testing the same drug.

Other recruiting trials for Total Knee Arthroplasty

Currently open trials in the same condition.

Other Rush University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05018091.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing